Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Stock Information for Citius Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Citius Oncology Anticipates Commercial Launch of LYMPHIR(TM) in 2025
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.